| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Gala-SR (1-100 μM, 24-72 h) significantly improved its compatibility with human U2OS cells through galactose modification [1]. Gala-SR (5 μM, 24 h) significantly upregulated the mRNA expression of G6Pase and FGF21, the direct target genes of RORα/γ, in HepG2 cells [1]. Gala-SR (5 μM) selectively enhanced the transcriptional activation activity of RORα in HEK293T cells [1]. After knockdown of RORα, the activation effect of Gala-SR (5 μM, 24 h) on G6Pase and FGF21 genes was significantly reduced [1]. Gala-SR (5 μM) mainly targets and activates RORα through its hydrolyzable galactose modification [1]. Gala-SR (2-5 μM) significantly enhanced the bioluminescence level and rhythm amplitude of the BMAL1 and Per2 reporter genes in U2OS cells and enhanced the expression of BMAL1 protein [1].
|
|---|---|
| ln Vivo |
Gala-SR (10 mg/kg, intraperitoneal injection 1 hour before light-off, once daily for 2 weeks) significantly enhanced the activity rhythm amplitude and total activity of SMCs [1]. Gala-SR (10 mg/kg, once daily when light-on) enhanced the luciferase neosynthesis signal of PER2::LUC knock-in myocardium, indicating enhanced BMAL1 expression [1]. Gala-SR (10 mg/kg, intraperitoneal injection, once daily for 3 weeks) restored the periodontal tissue rhythm amplitude in periodontitis mice, inhibited NF-κB inflammatory factors, and reduced periodontitis-related bone loss [1].
|
| Cell Assay |
Real Time qPCR[1]
Cell Types: HepG2 cells Tested Concentrations: 5 μM Incubation Duration: 24 h Experimental Results: Upregulated the mRNA expression of G6Pase and FGF21, direct target genes of RORα/γ, in HepG2 cells. |
| Animal Protocol |
Animal/Disease Models: C57BL/6J mice were first acclimatized to a 12-hour light/12-hour dark (L:D) condition for 2 weeks, and then switched to continuous darkness (D:D) to induce circadian rhythm disorder[1].
Doses: 10 mg/kg Route of Administration: 1 hour before the end of the light exposure, i.p., once daily for 2 weeks Experimental Results: Significantly enhanced the amplitude of the activity rhythm and the total activity level in mice. Animal/Disease Models: PER2::LUC gene knock-in mice[1]. Doses: 10 mg/kg Route of Administration: I.p., once, light start time Experimental Results: Enhanced liver luciferase signaling indicates increased BMAL1 expression. Animal/Disease Models: Male C57BL/6 mice, 2 months old, were housed under disrupted conditions for 4 weeks, and a ligature was placed around the cervix of the maxillary second molar to establish the murine periodontitis model[1]. Doses: 10 mg/kg Route of Administration: I.p., once daily for 3 weeks Experimental Results: Significantly reduced alveolar bone resorption (increased bone volume/total volume, reduced bone resorption height). Reduced inflammatory cell infiltration and osteoclast activity. Downregulated pro-inflammatory factors (TNF-α, IL-6) and upregulates anti-inflammatory factors (IL-10). |
| References |
| Molecular Formula |
C24H22F9NO8
|
|---|---|
| Molecular Weight |
623.42
|
| CAS # |
3092129-97-7
|
| Appearance |
Typically exists as solids at room temperature
|
| Synonyms |
Gala-SR1078
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6041 mL | 8.0203 mL | 16.0406 mL | |
| 5 mM | 0.3208 mL | 1.6041 mL | 3.2081 mL | |
| 10 mM | 0.1604 mL | 0.8020 mL | 1.6041 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
